Agustin Ezequiel Molinero

Ospedale Sacro Cuore Don Calabria

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Giulio Molon

Ospedale Sacro Cuore Don Calabria

Giovanni Targher

Ospedale Sacro Cuore Don Calabria

Stefano Bonapace

Ospedale Sacro Cuore Don Calabria

Riccardo Morandin

Azienda Ospedaliera Universitaria Integrata Verona

Alessandro Mantovani

Azienda Ospedaliera Universitaria Integrata Verona

Christopher D. Byrne

Southampton General Hospital

Gianluigi Lunardi

Ospedale Sacro Cuore Don Calabria

Tommaso De Ferrari

University of Messina

Antonio Parlavecchio

Fondazione Vincenzo Pansadoro

Lorenzo Pistelli

Azienda Ospedaliera Universitaria Pisana

Cooperative Institutions

University of Messina

Azienda Ospedaliera Universitaria Pisana

Azienda Ospedaliera Universitaria Policlinico "G. Martino"

Istituti di Ricovero e Cura a Carattere Scientifico

University of Pisa

Ospedale Cisanello

Ospedale Sacro Cuore Don Calabria

University of Verona

Ospedale Santa Chiara

Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

MI2AMI-CS: A meta-analysis comparing Impella and IABP outcomes in acute myocardial infarction-related cardiogenic shock

International Journal of Cardiology (2024)

Tommaso De Ferrari Lorenzo Pistelli Marco Franzino Agustin Ezequiel Molinero Giulia Azzurra De Santis

Cardiogenic Shock (CS) complicating acute myocardial infarction (AMI) poses a significant mortality risk, suggesting the opportunity to implement effective mechanical circulatory support strategies. The comparative efficacy of Intra-Aortic Balloon Pump (IABP) and Impella in managing CS-AMI remains a subject of investigation.

Impella

Intra-aortic balloon pump

10.1016/j.ijcard.2024.132411

Cite

Citations (3)

Ranolazine Unveiled: Rediscovering an Old Solution in a New Light

Journal of Clinical Medicine (2024)

Giulia Azzurra De Santis Tommaso De Ferrari Francesca Parisi Marco Franzino Agustin Ezequiel Molinero

Ranolazine is an anti-anginal medication that has demonstrated antiarrhythmic properties by inhibiting both late sodium and potassium currents. Studies have shown promising results for ranolazine in treating both atrial fibrillation and ventricular arrhythmias, particularly when used in combination with other medications. This review explores ranolazine's mechanisms of action and its potential role in cardiac arrhythmias treatment in light of previous clinical studies.

Ranolazine

10.3390/jcm13174985

Cite

Citations (0)

Ceramide‐based risk score CERT‐1 improves risk prediction for overall mortality and adverse cardiovascular outcomes in patients with and without cardiovascular disease: A prospective cohort study

Diabetes Obesity and Metabolism (2024)

Alessandro Mantovani Gianluigi Lunardi Stefano Bonapace Agustin Ezequiel Molinero Riccardo Morandin

Abstract Aims Whether the plasma‐based ceramide‐based risk score CERT1 improves risk prediction for cardiovascular disease (CVD) is uncertain. Materials and Methods Baseline and follow‐up data were combined from two cohorts, 334 patients with established/suspected CVD and 196 patients with type 2 diabetes followed for a median of 74 months (interquartile range 54–79 months). For the calculation of CERT1 risk score, we measured four specific plasma ceramides [Cer(d18:1/16:0), Cer(d18:1/18:0) and Cer(d18:1/24:1)] and their ratios to Cer(d18:1/24:0). Based on the CERT1 risk score, patients were split into four risk categories (low, moderate, increased or high risk). The primary outcome was a composite of overall mortality and incident nonfatal CVD outcomes (including myocardial infarction, ischaemic stroke or permanent atrial fibrillation). Results One hundred and thirty‐nine patients developed the primary composite outcome (72 nonfatal CVD outcomes and 67 total deaths) during follow‐up. Baseline CERT1 risk categories were significantly associated with the risk of developing the primary composite outcome (adjusted HR for high vs. low‐risk category 2.43, 95% CI 1.39–4.22, p = 0.002, and adjusted HR for increased vs. low‐risk category 2.16, 95% CI 1.28–3.63, p = 0.004). Receiver operator characteristic curve analysis showed that adding CERT1 risk score to traditional CVD risk factors and pre‐existing CVD, improved the discriminatory capability of the regression model for predicting the primary composite outcome (AUROC 0.691 [95% CI 0.674–0.769] vs. 0.722 [95% CI 0.642–0.742], p = 0.0275). Conclusions The ceramide‐based risk score CERT1 risk score improves risk prediction for long‐term risk of overall mortality and adverse cardiovascular outcomes in patients with and without CVD.

Interquartile range

Stroke

10.1111/dom.16156

Cite

Citations (0)

Author response for "Ceramide‐based risk score CERT‐1 improves risk prediction for overall mortality and adverse cardiovascular outcomes in patients with and without cardiovascular disease: A prospective cohort study"

Alessandro Mantovani Gianluigi Lunardi Stefano Bonapace Agustin Ezequiel Molinero Riccardo Morandin

10.1111/dom.16156/v2/response1

Cite

Citations (0)

Basal and post-stress ceramide-based risk score CERT1 predicts all-cause mortality and nonfatal myocardial infarction in patients with suspected or established coronary artery disease undergoing stress myocardial perfusion scintigraphy

Nutrition Metabolism and Cardiovascular Diseases (2024)